NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-CA-21-050 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).
Funding Opportunity RFA-CA-21-051 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support a coordinating center to facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN; see U01 awards supported under companion RFA-CA-21-050) that will conduct immunotherapy clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials. The network will include a representative from the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component. The awardee will contribute to the administration of a steering committee of required expertise--both inside and outside the U01 network, including the PD/PIs of the U01s, representatives of the COP, and the NCI Project Collaborators --to ensure that the goals of the network are accomplished. The Coordinating Center will have several responsibilities, including, but not limited to providing administrative support to the K9CIN: development and standardization of clinical protocols and correlative assays; implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; providing statistical support; facilitating sharing of agents, specimens, and data; harmonization of clinical data; and submission of clinical and correlative data to the Integrated Canine Data Commons.
Notice NOT-AR-21-027 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-033 from the NIH Guide for Grants and Contracts. The NINDS Materials to Enhance Training in Experimental Rigor (METER) UE5 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments. This UE5 FOA runs in parallel with a companion UC2 FOA that solicits applications for the NINDS center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), described in detail in RFA-NS-21-009.
Funding Opportunity RFA-NS-21-009 from the NIH Guide for Grants and Contracts. This is one of two Funding Opportunity Announcements (FOAs) that together aim to facilitate teaching of fundamental principles of rigorous biomedical research by developing an online educational resource for use by a broad range of researchers in an array of learning environments. The purpose of this FOA is to support the establishment of a center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), which will build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research.
Notice NOT-OD-21-153 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the U01 PDAC Stromal Reprogramming Consortium (PSRC) RFA-CA-21-041. The purpose of this FOA is to create a U24 Coordinating and Data Management Center (CDMC) that will support the overall coordination and research aims of the PSRC Research Projects. This FOA solicits U24 cooperative agreement applications from appropriate multidisciplinary groups that can assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative and data management activities of the PSRC. This FOA is open to any qualified applicant.
Funding Opportunity RFA-CA-21-041 from the NIH Guide for Grants and Contracts. Cut and paste
Notice NOT-CA-21-062 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-165 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-286 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.
Notice NOT-TW-21-007 from the NIH Guide for Grants and Contracts
Notice NOT-AR-21-026 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-004 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-036 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-134 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-290 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Notice NOT-AA-21-035 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-22-023 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit a cooperative agreement (U24) application for a Data Management and Coordinating Center (DMCC) which will support the integration of research activities across a group of ongoing human longevity translational projects and assume responsibilities for the management and expansion of the existing NIA Exceptional Longevity Portal (EL Portal). Specifically, the DMCC will facilitate and support collaborative research activities across the human longevity translational projects, manage the deposition and distribution of data and resources generated by these projects, as well as oversee outreach to and engagement of the broader scientific community to analyze the resources hosted by the EL Portal. The DMCC will also create a collaborative research workspace by leveraging the existing infrastructure of the NIA EL portalan interoperable resource, a scalable data commons which will combine multidimensional data, cloud computing, and software tools in a secure environment to allow investigators to access, deposit, and analyze different data types from multiple sources to accelerate the translation of molecular factors contributing to exceptional health and life span.
Funding Opportunity RFA-DA-22-033 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.